Curt Mikael von Euler-Chelpin

Member of the Board of Directors

Finansinspektionen (Sweden) Files from Sweden

Compiled from cited public records — every figure names the disclosure it came from, none copied from any wealth ranking. How we calculate this.

Positions on file
2
positions reconstructed from transactions reported to Finansinspektionen (FI) in Sweden

Not measurable for this profile: Reconstructed positions · 1-day change

Trading activity Jun 4, 2024 – Jul 9, 2026

Curt Mikael von Euler-Chelpin reported 9 transactions between Jun 4, 2024 and Jul 9, 2026. The buy and sell totals below count only code SACQ.

Open-market buys (SACQ)
148.4K SEK
4 purchases on file priced rows only
Open-market sales
None
0 sales on file
All reported transactions
9
every code, including awards and exercises
Pattern
Net buyer in the final 12 months of the window
last 12 months of the window

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

3 insiders bought XSpray Pharma AB (publ) shares worth 819,773 SEK between Jun 12, 2026 and Jun 18, 2026

Cluster buying

3 different insiders made 4 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.

3 insiders bought XSpray Pharma AB (publ) shares worth 819,773 SEK between Jun 12, 2026 and Jun 18, 2026
Date Insider Transaction Shares Price Value Filing
Jun 12, 2026 Blake Leitch SACQ Acquisition 44,939 14.80 SEK 664,977 SEK FI filing ↗
Jun 12, 2026 Anders Bladh SACQ Acquisition 2,010 14.86 SEK 29,869 SEK FI filing ↗
Jun 15, 2026 Blake Leitch SACQ Acquisition 5,061 15.14 SEK 76,628 SEK FI filing ↗
Jun 18, 2026 Curt Mikael von Euler-Chelpin SACQ Acquisition 3,000 16.10 SEK 48,300 SEK FI filing ↗

Total of the rows above: 819,773 SEK, in the currency the filings report.

Source: Finansinspektionen (Sweden); every row links to where it was published. Event computed Sep 14, 2026.

Reported transactions

Price 0.00 is a real reported figure on allotments, gifts and option exercises — not a missing number. The 9 most recent rows are grouped into 8 lines by date, company and transaction type — open a line to see every lot with its own source link.

How to read this list

Every row is one insider transaction as reported to FI, with a link back to the FI register filtered to that issuer and publication date. FI publishes no per-report permalink, so the link is a search, not a document. Where the record carries no price at all we leave the cell empty instead of guessing one.

The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.

  1. Annexin Pharmaceuticals AB (publ) SSUB Subscriptionnot a buy/sell decision 5,000 shares 60.0K SEK at 12.00 SEK FI filing ↗
  2. Spago Nanomedical AB (publ) SSUB Subscriptionnot a buy/sell decision 138,888 shares 15.3K SEK at 0.11 SEK FI filing ↗
  3. XSpray Pharma AB (publ) SACQ Acquisition 3,000 shares 48.3K SEK at 16.10 SEK FI filing ↗
  4. Dicot AB SSUB Subscriptionnot a buy/sell decision 51,006 shares 69.4K SEK at 1.36 SEK FI filing ↗
  5. Spago Nanomedical AB (publ) SSUB Subscriptionnot a buy/sell decision 624,996 shares 50.0K SEK at 0.08 SEK FI filing ↗
  6. Spago Nanomedical AB (publ) SACQ Acquisition 694,440 shares 694 SEK at 0.00 SEK FI filing ↗
  7. Dicot AB SACQ Acquisition × 2 188,000 shares 99.4K SEK
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    100,000 0.53 SEK 53.2K SEK FI filing ↗
    88,000 0.53 SEK 46.2K SEK FI filing ↗
  8. Annexin Pharmaceuticals AB (publ) SSUB Subscriptionnot a buy/sell decision 240,000 shares 60.0K SEK at 0.25 SEK FI filing ↗

Reconstructed positions

Reconstructed by adding up every transaction this person reported to FI since 2016. FI publishes transactions, not balances, so this is a computed figure, not a disclosed one — and it omits anything held before the register began.

What is not counted here

Each row comes from a public disclosure named on this page. Private companies, real estate, bonds and crypto are not in those disclosures and are therefore not counted here. Shares held through a holding company are recorded against that company, not against the individual behind it.

Equity positions reported to Finansinspektionen (FI) in Sweden, with the disclosure date shown on each row.
Issuer ISIN Security Shares Price Value Form Reported Filing
XSpray Pharma AB (publ) SE0009973563 XSpray Pharma AB 3,000 — — FI marknadssok.fi.se ↗
Dicot AB SE0011178458 Dicot 188,000 — — FI marknadssok.fi.se ↗

Other shareholders on record at the same companies

People who also appear on the shareholder record of a company where Curt Mikael von Euler-Chelpin reports shares.

Sharing a filing does not mean they work together day to day — it means both names appear on the same issuer’s insider record.

Sources

Every figure on this page is quoted from the public record named beside it, with the date it was true. Nothing here is our own calculation.

Think a number here is wrong? Check the named disclosure and its date against the tables above — how to report it.

Profile record last refreshed Sep 14, 2026.